{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:19:31Z","timestamp":1773296371568,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2016.12.009","type":"journal-article","created":{"date-parts":[[2017,1,21]],"date-time":"2017-01-21T01:31:45Z","timestamp":1484962305000},"page":"5463-5470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Stability and pre-formulation development of a plant-produced anthrax vaccine candidate"],"prefix":"10.1016","volume":"35","author":[{"given":"R. Mark","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devon","family":"Dubose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Chichester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slobodanka","family":"Manceva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Horsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Streatfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Breit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidadi","family":"Yusibov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.12.009_b0005","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1128\/CVI.00137-15","article-title":"Bacillus anthracis capsular conjugates elicit chimpanzee polyclonal antibodies that protect mice from pulmonary anthrax","volume":"22","author":"Chen","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.12.009_b0010","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1128\/CVI.00019-14","article-title":"Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant","volume":"21","author":"Feinen","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.12.009_b0015","unstructured":"Emergent BioSolutions. BioThrax\u00ae (Anthrax Vaccine Adsorbed). Package insert; 2015. <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/UCM074923.pdf>. [Accessed 2 September, 2016]."},{"issue":"3","key":"10.1016\/j.vaccine.2016.12.009_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8030069","article-title":"The ins and outs of anthrax toxin","volume":"8","author":"Friebe","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.vaccine.2016.12.009_b0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.biochem.75.103004.142728","article-title":"Anthrax toxin: receptor binding, internalization, pore formation, and translocation","volume":"76","author":"Young","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.vaccine.2016.12.009_b0030","doi-asserted-by":"crossref","first-page":"e00308","DOI":"10.7554\/eLife.00308","article-title":"Cdc48\/p97 promotes degradation of aberrant nascent polypeptides bound to the ribosome","volume":"2","author":"Verma","year":"2013","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2016.12.009_b0035","doi-asserted-by":"crossref","first-page":"39897","DOI":"10.1074\/jbc.M508569200","article-title":"Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen","volume":"280","author":"Zomber","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2016.12.009_b0040","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1002\/art.22818","article-title":"Low molecular weight isoforms of the aggrecanases are responsible for the cytokine-induced proteolysis of aggrecan in a porcine chondrocyte culture system","volume":"56","author":"Powell","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.vaccine.2016.12.009_b0045","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.jim.7000239","article-title":"Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis","volume":"28","author":"Ramirez","year":"2002","journal-title":"J Ind Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2016.12.009_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbiotec.2014.01.033","article-title":"Generation of protective immune response against anthrax by oral immunization with protective antigen plant-based vaccine","volume":"176","author":"Gorantala","year":"2014","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2016.12.009_b0055","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1086\/426865","article-title":"Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms","volume":"191","author":"Mikszta","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.009_b0060","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jps.20484","article-title":"Anthrax vaccine powder formulations for nasal mucosal delivery","volume":"95","author":"Jiang","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2016.12.009_b0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jps.22742","article-title":"Stable dry powder formulation for nasal delivery of anthrax vaccine","volume":"101","author":"Wang","year":"2012","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.vaccine.2016.12.009_b0070","first-page":"54","article-title":"Efficient scale-up strategy for spray-dried amorphous dispersions","volume":"13","author":"Dubose","year":"2013","journal-title":"Drug Dev Deliv"},{"key":"10.1016\/j.vaccine.2016.12.009_b0075","doi-asserted-by":"crossref","first-page":"e0153956","DOI":"10.1371\/journal.pone.0153956","article-title":"Production of functionally active and immunogenic non-glycosylated protective antigen from Bacillus anthracis in Nicotiana benthamiana by co-expression with peptide-N-glycosidase F (PNGase F) of Flavobacterium meningosepticum","volume":"11","author":"Mamedov","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.12.009_b0080","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1146\/annurev-arplant-050213-035850","article-title":"Plant molecular pharming for the treatment of chronic and infectious diseases","volume":"65","author":"Stoger","year":"2014","journal-title":"Annu Rev Plant Biol"},{"key":"10.1016\/j.vaccine.2016.12.009_b0085","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.biotechadv.2009.03.006","article-title":"Plants as bioreactors for the production of vaccine antigens","volume":"27","author":"Tiwari","year":"2009","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2016.12.009_b0090","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1467-7652.2010.00507.x","article-title":"Plant-made vaccines for humans and animals","volume":"8","author":"Rybicki","year":"2010","journal-title":"Plant Biotechnol J"},{"key":"10.1016\/j.vaccine.2016.12.009_b0095","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.biotechadv.2011.08.020","article-title":"Green factory: plants as bioproduction platforms for recombinant proteins","volume":"30","author":"Xu","year":"2012","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2016.12.009_b0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pbi.2004.01.015","article-title":"Posttranslational modification of therapeutic proteins in plants","volume":"7","author":"Gomord","year":"2004","journal-title":"Curr Opin Plant Biol"},{"key":"10.1016\/j.vaccine.2016.12.009_b0105","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4161\/hv.9777","article-title":"Is new always better than old?: the development of human vaccines for anthrax","volume":"5","author":"Baillie","year":"2009","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.vaccine.2016.12.009_b0110","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1128\/CVI.00240-12","article-title":"Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax","volume":"19","author":"Leffel","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.12.009_b0115","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1007\/s11095-014-1394-3","article-title":"Stabilization of HAC1 influenza vaccine by spray drying: formulation development and process scale-up","volume":"31","author":"Zhu","year":"2014","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2016.12.009_b0120","first-page":"4","article-title":"Scale-up of spray dried amorphous solid dispersions","volume":"19","author":"Santos","year":"2013","journal-title":"Eur Ind Pharm"},{"key":"10.1016\/j.vaccine.2016.12.009_b0125","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/CVI.00174-12","article-title":"Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant","volume":"19","author":"Wagner","year":"2012","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16312063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T23:53:23Z","timestamp":1536105203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16312063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":25,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X16312063"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stability and pre-formulation development of a plant-produced anthrax vaccine candidate","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}